Radiopharm Theranostics (RADX) announced positive interim Phase 2b data for RAD101 in suspected recurrent brain metastases, with 93% concordance between PET and MRI across evaluable lesions.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.